stockrow
Friday 6 November 2026
Export TPST’s income statement to Excel — free account
Tempest Therapeutics, Inc.
TPST Healthcare Biotechnology
- EPS
- +83.6%
- Free cash flow
- +67.0%
Quarter to June 2026, against a year earlier
0.38
0.08
−17.39%
Follow TPST
Alert me
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | — | — | — | — | — | — | — | — | — |
Altman Z-Score |
(1.96) | — | — | — | — | — | — | — | — | — |
P/S ratio |
83.76 | — | — | — | — | — | — | — | — | — |
P/FCF ratio |
0.00 | — | — | — | — | — | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
2.36 | — | — | — | — | — | — | — | — | — |
P/Operating CF |
(3.65) | — | — | — | — | — | — | — | — | — |
P/B ratio |
0.51 | — | — | — | — | — | — | — | — | — |
Price to Tangible BV |
0.51 | — | — | — | — | — | — | — | — | — |
EV/Sales |
(91.41) | — | — | — | — | — | — | — | — | — |
EV/EBITDA |
0.76 | — | — | — | — | — | — | — | — | — |
EV/Operating CF |
0.97 | — | — | — | — | — | — | — | — | — |
EV/FCF |
0.93 | — | — | — | — | — | — | — | — | — |
Quick Ratio |
8.66 | 4.56 | 8.15 | 5.17 | 5.84 | 2.59 | 4.29 | 4.17 | 2.13 | 2.33 |
Current Ratio |
8.82 | 4.82 | 8.50 | 5.68 | 6.15 | 3.44 | 4.53 | 4.29 | 2.21 | 2.50 |
Net Debt/EBITDA |
1.46 | 0.20 | 2.87 | 1.42 | 0.90 | 1.38 | 0.61 | 1.15 | 0.73 | 0.29 |
Debt/Assets |
0.00% | 3.90% | 0.68% | 0.50% | 7.55% | 20.58% | 22.50% | 12.14% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.18 | 0.01 | 0.01 | 0.10 | 0.42 | 0.57 | 0.23 | 0.00 | 0.00 |
Asset Turnover |
0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.75 | 0.24 | 0.87 | 0.92 | 0.99 | 0.92 | 0.87 | 0.93 | 0.79 | 1.02 |
Capex/Depreciation |
(0.89) | (0.14) | (1.12) | (0.38) | (0.15) | (0.36) | (0.88) | (0.45) | (1.12) | 0.00 |
Interest Coverage |
— | (292.80) | (200.55) | (43.74) | (214.42) | (21.05) | (21.41) | (20.12) | (31.93) | (128.38) |
| (69.99%) | 833.08% | 98.16% | (67.02%) | 430.58% | 173.23% | (131.70%) | (131.42%) | (182.35%) | (203.63%) | |
| (63.00%) | (118.83%) | (52.35%) | (56.04%) | (39.27%) | (58.90%) | (59.85%) | (60.38%) | (89.90%) | (89.91%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | (1,469.09%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(75.60%) | (540.54%) | (36.94%) | (71.95%) | (108.44%) | (56.55%) | (133.58%) | (92.76%) | (230.67%) | (472.34%) |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
Research and Development Expense of Revenue |
3,314.09% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
7,537.98% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
1,434.76% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
1.87 | — | — | — | — | — | — | — | — | — |
Graham Number |
0.00 | — | — | — | — | — | — | — | — | — |
Earnings Yield |
(152.84%) | — | — | — | — | — | — | — | — | — |
Free Cash Flow Yield |
(117.60%) | — | — | — | — | — | — | — | — | — |
Revenue per Share |
59.36 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(5,612.18) | (15,646.15) | (2,993.29) | (586.37) | (528.25) | (89.05) | (34.99) | (23.08) | (15.39) | (6.46) |
Capex per Share |
(235.09) | (3.08) | (4.56) | (5.65) | (1.39) | (0.46) | (0.63) | (0.14) | (0.20) | 0.00 |
Free Cash Flow per Share |
(5,847.27) | (15,649.23) | (2,997.85) | (592.02) | (529.64) | (89.51) | (35.62) | (23.22) | (15.59) | (6.46) |
Cash per Share |
10,398.91 | 13,556.15 | 9,837.47 | 903.44 | 522.78 | 177.80 | 35.17 | 33.09 | 14.10 | 1.86 |
Shareholders Equity per Share |
9,838.00 | 3,383.85 | 9,255.95 | 851.65 | 497.61 | 123.90 | 20.39 | 22.58 | 8.91 | 1.61 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
9,838.00 | 3,383.85 | 9,255.95 | 851.65 | 497.61 | 123.90 | 20.39 | 22.58 | 8.91 | 1.61 |
Free Cash Flow |
(64.32) | (20.34) | (23.68) | (41.62) | (19.07) | (26.09) | (31.63) | (27.53) | (33.46) | (26.82) |
Working Capital |
103.24 | 15.65 | 73.61 | 58.61 | 16.60 | 48.94 | 25.67 | 30.95 | 17.25 | 4.96 |
Capital Expenditures |
(2.59) | 0.00 | (0.04) | (0.40) | (0.05) | (0.13) | (0.56) | (0.17) | (0.43) | — |
Net Current Asset Value |
102.12 | 4.33 | 72.47 | 56.03 | 14.88 | 31.84 | 4.97 | 15.53 | 9.11 | (1.99) |
EV/EBIT |
0.74 | — | — | — | — | — | — | — | — | — |
Capex to Sales |
3.96 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Price to Operating Income |
0.00 | — | — | — | — | — | — | — | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.52 | 0.00 | 0.00 | 0.32 | 0.31 | 0.34 | 0.60 | 0.45 | 0.44 | 0.44 |
Cash ROIC |
(28.89%) | (89.25%) | (15.64%) | (33.63%) | (49.57%) | (25.33%) | (52.98%) | (38.09%) | (67.75%) | (186.57%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
Accounts Payable Turnover |
1.95 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
147.53 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Receivables |
— | 1.68 | 1.68 | 1.80 | 0.77 | — | — | — | — | — |
Average Payables |
2.77 | 1.74 | 1.65 | 1.75 | 1.28 | 1.03 | 1.05 | 0.98 | 1.65 | 1.74 |
Average Assets |
130.58 | 71.18 | 51.94 | 79.52 | 48.92 | 48.05 | 59.66 | 48.85 | 46.55 | 29.21 |
Average Common Equity |
117.53 | (10.15) | (27.70) | 66.50 | (4.46) | (16.34) | 27.11 | 22.44 | 22.95 | 12.90 |
Columns are period end dates · fundamentals updated 26 Oct 2026